Four patients discontinued SGLT-2 inhibitors: two due to erythrocytosis (one resolved spontaneously, and one improved with phlebotomy) and two due to well-controlled diabetes (Supplementary Fig. 3). This evidence concerns the gene SLC5A2 and polycythemia.